פרופ' מיטל גל-תנעמי

1: Huang CF^†, Awad MH^†, Gal-Tanamy M^*, Yu ML^*. Perspective of the risk and molecular mechanisms of hepatocellular carcinoma after HCV eradication in the post-DAA era. Clin Mol Hepatol. 2024 Jul 1. doi: 10.3350/cmh.2024.0472. Epub ahead of print. PMID: 38946463. ^† co-first author^* co-corresponding

2: Huang CF^†, Awad MH^†, Gal-Tanamy M^*, Yu ML^*. Unmet needs in the post-DAA era: the risk and molecular mechanisms of hepatocellular carcinoma after HCV eradication.Clin Mol Hepatol. 2024 Apr 26. doi: 10.3350/cmh.2024.0155. Epub ahead of print.PMID: 38665034. ^† co-first author^* co-corresponding

3: Alter HJ, Barnes E, Biondi MJ, Cox AL, Eberts JD, Feld JJ, Liang TJ, Morrison J, Rice CM, Shoukry NH, Thomas DL, Van Gennip J, Weijer C; other signatories.Joint statement in support of hepatitis C human challenge studies. Lancet Gastroenterol Hepatol. 2023 Nov;8(11):967-969. doi: 10.1016/S2468-1253(23)00314-X. Epub 2023 Sep 21. PMID: 37742699.

4: Safra M, Tamari Z, Polak P, Shiber S, Matan M, Karameh H, Helviz Y, Levy- Barda A, Yahalom V, Peretz A, Ben-Chetrit E, Brenner B, Tuller T, Gal-Tanamy M, Yaari G. Altered somatic hypermutation patterns in COVID-19 patients classifies disease severity. Front Immunol. 2023 Apr 19;14:1031914. doi: 10.3389/fimmu.2023.1031914. PMID: 37153628; PMCID: PMC10154551.

5: Perez S^†, Lavi-Itzkovitz A^†, Gidoni M^†, Domovitz T, Dabour R, Khurana I, Davidovich A, Tobar A, Livoff A, Solomonov E, Maman Y, El-Osta A, Tsai Y, Yu ML, Stemmer SM, Haviv I^*, Yaari G^*, Gal-Tanamy M^*. High-Resolution Genomic Profiling of Liver Cancer Links Etiology With Mutation and Epigenetic Signatures. Cell Mol Gastroenterol Hepatol. 2023;16(1):63-81. doi: 10.1016/j.jcmgh.2023.03.004. Epub 2023 Mar 24. PMID: 36965814; PMCID: PMC10212990. ^† co-first author^* co-corresponding

6: Domovitz T^†, Ayoub S^†, Werbner M^†, Alter J, Izhaki Tavor L, Yahalom-Ronen Y, Tikhonov E, Meirson T, Maman Y, Paran N, Israely T, Dessau M, Gal-Tanamy M. HCV Infection Increases the Expression of ACE2 Receptor, Leading to Enhanced Entry of Both HCV and SARS-CoV-2 into Hepatocytes and a Coinfection State. Microbiol Spectr. 2022 Dec 21;10(6):e0115022. doi: 10.1128/spectrum.01150-22. Epub 2022 Oct 31. PMID: 36314945; PMCID: PMC9769977.^† co-first author

7: Yamin K, Bijlani S, Berman J, Soni A, Shlomai J, Buragohain BM, Werbner M, Gal-Tanamy M, Matityahu A, Onn I. Fold-change of chromatin condensation in yeast is a conserved property. Sci Rep. 2022 Oct 17;12(1):17393. doi: 10.1038/s41598-022-22340-8. PMID: 36253460; PMCID: PMC9576780.

8: Li R, Mor M, Ma B, Clark AE, Alter J, Werbner M, Lee JC, Leibel SL, Carlin AF, Dessau M, Gal-Tanamy M, Croker BA, Xiang Y, Freund NT. Conformational flexibility in neutralization of SARS-CoV-2 by naturally elicited anti-SARS- CoV-2 antibodies. Commun Biol. 2022 Aug 5;5(1):789. doi: 10.1038/s42003-022-03739-5. PMID: 35931732; PMCID: PMC9355996.

9: Rabinowitz KM, Navon M, Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y, Pauker MH, Friedenberg A, Levy-Barda A, Segal A, Broitman Y, Maoz E, Ovadia B, Aharoni Golan M, Shachar E, Ben-Horin S, Maharshak N, Mor M, Ben Zvi H, Eliakim R, Barkan R, Sharar-Fischler T, Goren S, Krugliak N, Pichinuk E, Mor M, Werbner M, Alter J, Abu-Taha H, Kaboub K, Dessau M, Gal-Tanamy M, Cohen D, Freund NT, Dotan I, On Behalf Of The Responses To Covid-Vaccine Israeli Ibd. Anti-TNFα Treatment Impairs Long-Term Immune Responses to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases. Vaccines (Basel). 2022 Jul 26;10(8):1186. doi: 10.3390/vaccines10081186. PMID: 35893835; PMCID: PMC9330864.

10: Samuels H, Malov M, Saha Detroja T, Ben Zaken K, Bloch N, Gal-Tanamy M, Avni O, Polis B, Samson AO. Autoimmune Disease Classification Based on PubMed Text Mining. J Clin Med. 2022 Jul 26;11(15):4345. doi: 10.3390/jcm11154345. PMID: 35893435; PMCID: PMC9369164.

11: Ashur I, Alter J, Werbner M, Ogungbile A, Dessau M, Gal-Tanamy M, Vernick S. Rapid electrochemical immunodetection of SARS-CoV-2 using a pseudo-typed vesicular stomatitis virus model. Talanta. 2022 Mar 1;239:123147. doi:

10.1016/j.talanta.2021.123147. Epub 2021 Dec 13. PMID: 34920254; PMCID: PMC8667521.

12: Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, Rabinowitz KM, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y, Pauker MH, Friedenberg A, Levy-Barda A, Segal A, Broitman Y, Maoz E, Ovadia B, Golan MA, Shachar E, Ben-Horin S, Perets TT, Ben Zvi H, Eliakim R, Barkan R, Goren S, Navon M, Krugliak N, Werbner M, Alter J, Dessau M, Gal-Tanamy M, Freund NT, Cohen D, Dotan I; REsponses to COVid-19 vaccinE IsRaeli IBD group (RECOVER). Lower Serologic Response to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases Treated With Anti-TNFα. Gastroenterology. 2022 Feb;162(2):454-467. doi: 10.1053/j.gastro.2021.10.029. Epub 2021 Oct 28. PMID: 34717923; PMCID: PMC8552587.

13: Rosenberg-Friedman M, Kigel A, Bahar Y, Werbner M, Alter J, Yogev Y, Dror Y, Lubetzky R, Dessau M, Gal-Tanamy M, Many A, Wine Y. BNT162b2 mRNA vaccine elicited antibody response in blood and milk of breastfeeding women. Nat Commun. 2021 Oct 28;12(1):6222. doi: 10.1038/s41467-021-26507-1. PMID: 34711825; PMCID: PMC8553805.

14: Mor M, Werbner M, Alter J, Safra M, Chomsky E, Lee JC, Hada-Neeman S, Polonsky K, Nowell CJ, Clark AE, Roitburd-Berman A, Ben-Shalom N, Navon M, Rafael D, Sharim H, Kiner E, Griffis ER, Gershoni JM, Kobiler O, Leibel SL, Zimhony O, Carlin AF, Yaari G, Dessau M, Gal-Tanamy M, Hagin D, Croker BA, Freund NT. Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors. PLoS Pathog. 2021 Feb 11;17(2):e1009165. doi: 10.1371/journal.ppat.1009165. PMID: 33571304; PMCID: PMC7877634.

15: Domovitz T, Gal-Tanamy M. Tracking Down the Epigenetic Footprint of HCV- Induced Hepatocarcinogenesis. J Clin Med. 2021 Feb 2;10(3):551. doi: 10.3390/jcm10030551. PMID: 33540858; PMCID: PMC7867330.

16: Zucker I, Lester Y, Alter J, Werbner M, Yecheskel Y, Gal-Tanamy M, Dessau M. Pseudoviruses for the assessment of coronavirus disinfection by ozone. Environ Chem Lett. 2021;19(2):1779-1785. doi: 10.1007/s10311-020-01160-0. Epub 2021 Jan 13. PMID: 33462542; PMCID: PMC7805571.

17: Mor M, Werbner M, Alter J, Safra M, Chomsky E, Hada-Neeman S, Polonsky K, Nowell CJ, Clark AE, Roitburd-Berman A, Shalom NB, Navon M, Rafael D, Sharim H, Kiner E, Griffis E, Gershoni JM, Kobiler O, Leibel SL, Zimhony O, Carlin AF, Yaari G, Dassau M, Gal-Tanamy M, Hagin D, Croker BA, Freund NT. Multi-Clonal Live SARS-CoV-2 In Vitro Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors. bioRxiv [Preprint]. 2020 Oct 6:2020.10.06.323634. doi: 10.1101/2020.10.06.323634. Update in: PLoS Pathog. 2021 Feb 11;17(2):e1009165. doi: 10.1371/journal.ppat.1009165. PMID: 33052341; PMCID: PMC7553166.

18: Ninio L^†, Nissani A^†, Meirson T^†, Domovitz T, Genna A, Twafra S, Srikanth KD, Dabour R, Avraham E, Davidovich A, Gil-Henn H^*, Gal-Tanamy M^*. Hepatitis C Virus Enhances the Invasiveness of Hepatocellular Carcinoma via EGFR-Mediated Invadopodia Formation and Activation. Cells. 2019 Nov 5;8(11):1395. doi: 10.3390/cells8111395. PMID: 31694343; PMCID: PMC6912298. ^† co-first author^* co-corresponding

19: Gal-Tanamy M. Multi-omic Analyses Reveal Complex Interactions Between HCV and Hepatocytes Demonstrating That the Red Queen Is Up and Running. Gastroenterology. 2019 Aug;157(2):300-302. doi: 10.1053/j.gastro.2019.06.005. Epub 2019 Jun 13. PMID: 31255661.

20: Perez S^†, Kaspi A^†, Domovitz T^†, Davidovich A, Lavi-Itzkovitz A, Meirson T, Alison Holmes J, Dai CY, Huang CF, Chung RT, Nimer A, El-Osta A, Yaari G, Stemmer SM, Yu ML^*, Haviv I^*, Gal-Tanamy M^*. Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals. PLoS Genet. 2019 Jun 19;15(6):e1008181. doi: 10.1371/journal.pgen.1008181. PMID: 31216276; PMCID: PMC6602261. ^† co-first author^* co-corresponding

21: Perez S^†, Gevor M^†, Davidovich A^†, Kaspi A, Yamin K, Domovich T, Meirson T, Matityahu A, Brody Y, Stemmer SM, El-Osta A, Haviv I, Onn I^*, Gal-Tanamy M^*. Dysregulation of the cohesin subunit RAD21 by Hepatitis C virus mediates host- virus interactions. Nucleic Acids Res. 2019 Mar 18;47(5):2455-2471. doi: 10.1093/nar/gkz052. PMID: 30698808; PMCID: PMC6412124. ^† co-first author^* co-corresponding

22: Perez S, Gal-Tanamy M. Studying the Hepatitis C Virus-Induced Epigenetic Signature After Cure with Direct-Acting Antivirals. Methods Mol Biol. 2019;1911:191-207. doi: 10.1007/978-1-4939-8976-8_13. PMID: 30593627.

23: Eliyahu S^†, Sharabi O^†, Elmedvi S^†, Timor R, Davidovich A, Vigneault F, Clouser C, Hope R, Nimer A, Braun M, Weiss YY, Polak P, Yaari G^*, Gal-Tanamy M^*. Antibody Repertoire Analysis of Hepatitis C Virus Infections Identifies Immune Signatures Associated With Spontaneous Clearance. Front Immunol. 2018 Dec 21;9:3004. doi: 10.3389/fimmu.2018.03004. PMID: 30622532; PMCID: PMC6308210. ^† co-first author^* co-corresponding

24: Shapira A, Shapira S, Gal-Tanamy M, Zemel R, Tur-Kaspa R, Benhar I. Removal of hepatitis C virus-infected cells by a zymogenized bacterial toxin. PLoS One. 2012;7(2):e32320. doi: 10.1371/journal.pone.0032320. Epub 2012 Feb 16. PMID: 22359682; PMCID: PMC3281143.

25: Gal-Tanamy M, Bachmetov L, Ravid A, Koren R, Erman A, Tur-Kaspa R, Zemel R. Vitamin D: an innate antiviral agent suppressing hepatitis C virus in human hepatocytes. Hepatology. 2011 Nov;54(5):1570-9. doi: 10.1002/hep.24575. PMID: 21793032. 26: Shapira A, Gal-Tanamy M, Nahary L, Litvak-Greenfeld D, Zemel R, Tur-Kaspa R, Benhar I. Engineered toxins "zymoxins" are activated by the HCV NS3 protease by removal of an inhibitory protein domain. PLoS One. 2011 Jan 14;6(1):e15916. doi: 10.1371/journal.pone.0015916. PMID: 21264238; PMCID: PMC3021518.

27: Gal-Tanamy M, Zemel R, Bachmatov L, Jangra RK, Shapira A, Villanueva RA, Yi M, Lemon SM, Benhar I, Tur-Kaspa R. Inhibition of protease-inhibitor-resistant hepatitis C virus replicons and infectious virus by intracellular intrabodies. Antiviral Res. 2010 Oct;88(1):95-106. doi: 10.1016/j.antiviral.2010.08.001. Epub 2010 Aug 10. PMID: 20705106; PMCID: PMC4418563.

28: Gal-Tanamy M, Keck ZY, Yi M, McKeating JA, Patel AH, Foung SK, Lemon SM. In vitro selection of a neutralization-resistant hepatitis C virus escape mutant. Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19450-5. doi: 10.1073/pnas.0809879105. Epub 2008 Dec 3. PMID: 19052239; PMCID: PMC2614781.

29: Keck ZY, Li TK, Xia J, Gal-Tanamy M, Olson O, Li SH, Patel AH, Ball JK, Lemon SM, Foung SK. Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies. J Virol. 2008 Jun;82(12):6061-6. doi: 10.1128/JVI.02475-07. Epub 2008 Apr 9. PMID: 18400849; PMCID: PMC2395155.

30: Keck ZY, Olson O, Gal-Tanamy M, Xia J, Patel AH, Dreux M, Cosset FL, Lemon SM, Foung SK. A point mutation leading to hepatitis C virus escape from neutralization by a monoclonal antibody to a conserved conformational epitope. J Virol. 2008 Jun;82(12):6067-72. doi: 10.1128/JVI.00252-08. Epub 2008 Apr 2. PMID: 18385242; PMCID: PMC2395135.

31: Trahtenherts A, Gal-Tanamy M, Zemel R, Bachmatov L, Loewenstein S, Tur-Kaspa R, Benhar I. Inhibition of hepatitis C virus RNA replicons by peptide aptamers. Antiviral Res. 2008 Mar;77(3):195-205. doi: 10.1016/j.antiviral.2007.12.013. Epub 2008 Jan 22. PMID: 18243349.

32: Gal-Tanamy M, Zemel R, Berdichevsky Y, Bachmatov L, Tur-Kaspa R, Benhar I. HCV NS3 serine protease-neutralizing single-chain antibodies isolated by a novel genetic screen. J Mol Biol. 2005 Apr 15;347(5):991-1003. doi: 10.1016/j.jmb.2005.02.020. PMID: 15784258.

33: Gargir A, Ofek I, Meron-Sudai S, Tanamy MG, Kabouridis PS, Nissim A. Single chain antibodies specific for fatty acids derived from a semi-synthetic phage display library. Biochim Biophys Acta. 2002 Jan 15;1569(1-3):167-73. doi: 10.1016/s0304-4165(01)00245-8. PMID: 11853971.